Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 500

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 12
Chunk 500
---
    Rule 13a-14(a) Certification of Principal Financial Officer
  
    32.1**
    
    Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Principal Executive Officer and Principal Financial Officer
  
    97.1*
    
    Compensation Recovery Policy.
  
    101.INS*
     
    Inline
    XBRL Instance Document
  
    101.SCH*
     
    Inline
    XBRL Taxonomy Extension Schema Document
  
    101.CAL*
     
    Inline
    XBRL Taxonomy Extension Calculation Linkbase
  
    101.DEF*
     
    Inline
    XBRL Taxonomy Extension Definition Linkbase
  
    101.LAB*
     
    Inline
    XBRL Taxonomy Extension Labels Linkbase
  
    101.PRE*
     
    Inline
    XBRL Taxonomy Extension Presentation Linkbase
  
    104*
     
    Cover
    Page Interactive Data File (embedded within the Inline XBRL document)

*
Filed herewith.

**
Furnished herewith.

†
Management contracts, compensation plans and arrangements.

Item
16. Form 10-K Summary

Not
applicable.

124

JUPITER
NEUROSCIENCES, INC.

Index
to Financial Statements

    Report
    of Independent Registered Public Accounting Firm Assurance Dimensions, LLC PCAOB ID: 5036
    F-2

    Balance Sheets as of December 31, 2024 and 2023
    F-3

    Statements of Operations for the Years Ended December 31, 2024 and 2023
    F-4

    Statements
    of Changes in Stockholders’ Equity (Deficit) for the Years Ended December 31, 2024 and 2023
    F-5

    Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023
    F-6

    Notes to Financial Statements
    F-7

F-1

REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To
the Stockholders and Board of Directors of

Jupiter
Neurosciences, Inc

Opinion
on the Financial Statements

We
have audited the accompanying balance sheets of Jupiter Neurosciences, Inc, (the Company) as of December 31, 2024 and